Al Baraka Fertility Hospital
10
0
0
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 10 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
ARTIFICIAL INTELLIGENCE IN REPRODUCTIVE MEDICINE
Role: lead
The Impact of the Previous Exposure to Covid-19 Virus Infection on the Outcome of ICSI Cycles
Role: lead
Role of Atosiban in Recurrent Implantation Failure
Role: lead
Dual Trigger, Urinary HCG or Recombinant HCG, Which is the Best !?
Role: lead
Utilizing Free DNA in Embryo Culture for PGT
Role: lead
AMH and Pregnancy Outcome in IVF
Role: lead
The Association Between Serum E2 and P on the Day of FET and the Pregnancy Outcome
Role: lead
Novel Therapy for Poor Responders Management
Role: lead
Novel Approach With Double Agent Artificial Oocyte Activation for Repeated Fertilization Failure Due to Combined Sperm and Oocyte Factor
Role: collaborator
Artificial Oocyte Activation Comparing Tow Different Agents
Role: collaborator
All 10 trials loaded